Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children

NEXT STORY
North America Transient Protein Expression Market Report 2021-2027: Market is Expected Witness High Demand for Systems for Drug Discovery Applications
PREV STORY
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Hyris Fully Embraces the Immunology Sector to Better Fight COVID-19 and Beyond, Presenting Its New, Disruptive T-Cell Test to the International Conference ‘A-Wish’

author_avatar
NASDAQ Market News

SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting

- Galinpepimut-S (GPS) induced immune activation against Wilms tumor-1 (WT1) antigen as well as ...

author_avatar
NASDAQ Market News

Cellectar Biosciences to Host Conference Call on March 10 to Report Year End 2015 Financials, Corporate Performance and 2016 Objectives

MADISON, Wis., March 07, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused ...

author_avatar
NASDAQ Market News